Elicio Therapeutics, Inc. (ELTX)
NASDAQ: ELTX · Real-Time Price · USD
11.69
-0.16 (-1.35%)
Apr 24, 2026, 4:00 PM EDT - Market closed
Elicio Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
The company presented updates on its AMP platform for lymph node-targeted immunotherapies, highlighting strong clinical results for ELI-002 in KRAS-mutant cancers, robust T cell responses, and a favorable safety profile. Phase II results are expected in H1 2026, with plans for pipeline expansion and a Phase III trial.
Fiscal Year 2025
-
AMP vaccine technology enables potent immune responses by targeting lymph nodes, with ELI-002 showing strong safety, robust T cell activation, and promising early clinical signals in KRAS-mutant pancreatic cancer. The phase 2 trial is fully enrolled, with interim analysis expected in Q3.